| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000016410 |
| Receipt No. | R000019010 |
| Official scientific title of the study | Randomized comparative study for efficacy of esomeprazole and lansoprazole in the prevention of recurrent gastroduodenal ulcer in patients continuously treated with non-steroidal anti-inflammatory drugs |
| Date of disclosure of the study information | 2015/02/02 |
| Last modified on | 2017/02/02 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Randomized comparative study for efficacy of esomeprazole and lansoprazole in the prevention of recurrent gastroduodenal ulcer in patients continuously treated with non-steroidal anti-inflammatory drugs | |
| Title of the study (Brief title) | EPZvsLPZ study | |
| Region |
|
|
| Condition | ||
| Condition | Gastroduodenal ulcer | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The aim of this study is to evaluate the efficacy of esomeprazole 20mg and lansoprazole 15mg in the prevention of recurrent gastroduodenal ulcer in patients continuously treated with non-steroidal anti-inflammatory drugs |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Non-recurrent rate of gastroduodenal ulcer |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Esomeprazole 20mg once a day for 12 months | |
| Interventions/Control_2 | Lansoprazole 15mg once a day for 12 months | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) patients with endoscopic diagnosed as gastroduodenal ulcer scar, and continuously treated with non-steroidal anti-inflammatory drugs
2) patients accepted to registration for this study 3) patients with informed consent |
|||
| Key exclusion criteria | 1) Patients with severe heart disease, acute cerebrovascular disease, hematological disease, severe liver disease, severe renal disease, or malignancy.
2) Pregnant women 3) Patients treated with Reyataz or Edulant 4) Patients with allergy for proton pump inhibitor 5) Patients with active gastroduodenal ulcers on the first time of this study 6) Patients with operative history of esophagus or stomach 7) Patients treated with steroids 8) Patients with alcoholism or drug dependence 9) Patients judged as unsuitable by investigator |
|||
| Target sample size | 260 | |||
| Research contact person | |
| Name of lead principal investigator | Naohiko Harada |
| Organization | National Hospital Organization Kyushu Medical Center |
| Division name | Department of Gastroenterology |
| Address | 1-8-1 Jigyohama, Chuo-ku, Fukuoka 810-8563, Japan |
| TEL | 092-852-0700 |
| haradan@kyumed.jp | |
| Public contact | |
| Name of contact person | Naohiko Harada |
| Organization | National Hospital Organization Kyushu Medical Center |
| Division name | Department of Gastroenterology |
| Address | 1-8-1 Jigyohama, Chuo-ku, Fukuoka 810-8563, Japan |
| TEL | 092-852-0700 |
| Homepage URL | |
| haradan@kyumed.jp | |
| Sponsor | |
| Institute | National Hospital Organization |
| Institute | |
| Department | |
| Funding Source | |
| Organization | National Hospital Organization |
| Organization | |
| Division | |
| Category of Funding Organization | |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000019010 |